BPC-157
InvestigationalA synthetic peptide with extensive preclinical interest around tissue repair and GI biology, but limited reliable human evidence.
Human Evidence●○○○○
Preclinical●●●●○
Promising — not proven
Explore profile →OUTCOME INTELLIGENCE · RECOVERY
Recovery
Healing is not one biological process—and no single peptide owns it.
Recovery spans inflammation, pain signaling, connective-tissue remodeling, blood flow, sleep and the return of function after stress or injury. The useful question is not “What heals fastest?” It is: what outcome was actually measured in humans?
The question that matters
Does a compound improve a meaningful human outcome—or only a biomarker, animal model or plausible pathway?
Recovery is one of the clearest places where compelling biology, intense community adoption and clinical evidence can diverge.
01 / DEFINE THE OUTCOME
What “recovery” actually means.
The biohacking conversation often compresses pain relief, tissue repair, inflammation and performance readiness into one word: healing. They are not interchangeable endpoints.
InflammationImmune signaling and the resolution of inflammatory responses.
PainSymptom intensity and pain signaling—not necessarily structural repair.
Tissue remodelingTendon, ligament, muscle, skin and connective-tissue biology.
FunctionReturn of movement, strength, workload tolerance or daily activity.
Sleep & restorationRecovery-supporting physiology that can affect readiness without directly repairing tissue.
TimeNatural healing and regression to the mean can make uncontrolled anecdotes especially difficult to interpret.
02 / THE LANDSCAPE
Peptides connected to the recovery conversation.
These compounds enter the category for very different reasons. A high preclinical score is not a substitute for demonstrated human recovery outcomes.
TB-500
InvestigationalA synthetic fragment related to thymosin beta-4 that is widely discussed for recovery, while reliable human efficacy data remain very limited.
Human Evidence●○○○○
Preclinical●●●○○
Popular — not clinically established
Explore profile →Cibinetide (ARA-290)
InvestigationalA non-erythropoietic peptide derived from erythropoietin signaling, studied in humans for neuropathic pain and tissue-protective effects.
Human Evidence●●●○○
Preclinical●●●●○
Human signal exists — not an approved repair therapy
Explore profile →GHK-Cu
Route-dependent / investigationalA naturally occurring copper-binding peptide with decades of interest in skin biology and wound repair; evidence varies sharply by formulation and route.
Human Evidence●●○○○
Preclinical●●●●○
Too broad
Explore profile →KPV
InvestigationalA short peptide fragment associated with melanocortin biology and anti-inflammatory research, with most enthusiasm running ahead of clinical evidence.
Human Evidence●○○○○
Preclinical●●●○○
Not established in humans
Explore profile →Sermorelin
Prescription peptide / historical FDA productA GHRH(1-29) analog that stimulates endogenous growth hormone release and is used clinically in some compounded settings.
Human Evidence●●●○○
Preclinical●●●●○
Mechanistically plausible — broader anti-aging claims exceed evidence
Explore profile →Ipamorelin
Investigational / compounded useA selective ghrelin-receptor agonist studied for growth-hormone release and gastrointestinal motility, with limited evidence for common biohacking claims.
Human Evidence●●○○○
Preclinical●●●○○
Not established for general wellness
Explore profile →CJC-1295
InvestigationalA long-acting GHRH analog designed to increase growth hormone and IGF-1 exposure; clinical development remained limited.
Human Evidence●●○○○
Preclinical●●●○○
Hormonal effects documented — performance claims unproven
Explore profile →Evidence scores are editorial orientation, not treatment rankings. Open each profile for the underlying evidence, limitations and regulatory context.
03 / COMMUNITY SIGNAL
What people are talking about.
BPC-157 and thymosin-related compounds dominate recovery discussion, creating one of the category's largest gaps between community adoption and controlled human evidence.
Community ≠ Clinical Guidance. Public discussion can reveal attention, recurring claims and user-reported patterns. It cannot establish efficacy, safety or an appropriate treatment protocol.
04 / CLAIM VS EVIDENCE
Where the recovery story outruns the data.
“It reduced my pain, so it healed the injury.”Pain improvement and structural tissue repair are different outcomes. One does not prove the other.
“Animal tendon data means it works for human injuries.”Preclinical repair models can establish biological plausibility. Translation into reproducible human benefit requires human trials.
“TB-500 has human thymosin beta-4 evidence.”TB-500 is a fragment related to full-length thymosin beta-4. Evidence from the full-length molecule should not automatically be attributed to TB-500.
“Lots of positive reports make BPC-157 established.”Community volume is an attention signal. BPC-157's controlled human evidence remains extremely limited.
The editorial rule: separate symptom change, biological mechanism and actual tissue-healing outcomes. Then ask whether the evidence came from humans.
05 / BEYOND THE INDEX
The outcome is bigger than peptides.
BIOHACKING. EVOLVED. starts with peptides, but recovery science does not end there.
Future coverage will follow the strongest evidence across rehabilitation, sleep, nutrition, diagnostics, wearables, biologics, pain science, training-load management and emerging therapeutics—whether a peptide is involved or not.
06 / KEEP READING
Follow the evidence.
Deep Dive
BPC-157
Recovery's most talked-about peptide—and one of its biggest evidence gaps.
Evidence Lesson
TB-500
Why evidence from a related molecule cannot simply be transferred to the compound people are discussing.
Inflammation
KPV
A broad preclinical anti-inflammatory story with almost no human therapeutic evidence.
Research System
The Peptide Index
Compare evidence maturity, Community Signal, The Gap and regulatory status across the broader library.
Editorial note: BIOHACKING. EVOLVED. is an educational publication, not a medical provider. This Outcome Hub does not provide diagnosis, dosing, sourcing, treatment or prescribing guidance. Recovery claims should be evaluated against the specific human outcome studied, the product/formulation used and the quality of the underlying evidence.